webinar register page

Webinar banner
A clinical and scientific perspective on lecanemab - UK DRI virtual roundtable
The UK Dementia Research Institute welcomes you to a virtual roundtable to discuss the promising Phase III trial data of lecanemab for the treatment of Alzheimer’s disease, following presentation of results from Eisai/Biogen at CTAD (Nov 29).

An expert panel of clinicians and basic researchers will dig into the data, providing their perspective on what the results mean for amyloid therapies, drug discovery, trial design, the next steps and more.

- Dr Catherine Mummery
- Prof James Rowe
- Prof Bart De Strooper
- Prof Clare Mackay

Chaired by Prof Jonathan Schott & and Dr Giovanna Lalli

Following panellist presentations, there will be an opportunity for audience Q&A and discussion.

The roundtable is intended for an audience of discovery scientists, clinicians, industry and experts in dementia research and drug development field.

Dec 13, 2022 04:00 PM in London

* Required information


Prof Jonathan Schott
Prof of Neurology at the Dementia Research Centre, UCL Institute of Neurology, Honorary consultant neurologist @National Hospital for Neurology and Neurosurgery, Queen Square, & UK DRI Co-investigator
Prof Schott leads several translational clinical research projects in the dementias, with particular interest in how clinical assessment, imaging and fluid (blood and CSF) biomarkers and genetics can be combined to improve differential diagnosis and identify pre-symptomatic Alzheimer’s disease and other forms of dementia. This include Insight 46, a major neuroimaging study of the MRC National Survey of Health and Development British 1946 Birth Cohort.
Dr Catherine Mummery
Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Clinical lead @NHNN Cognitive Disorders Clinic, and NIHR UCLH BRC Academic Lead and Head
Dr Catherine Mummery is head of novel therapeutics at the Dementia Research Centre, UCL, and has been senior investigator on over 20 early phase drug trials of disease modifying agents in dementias including genetic forms of Alzheimer’s disease and frontotemporal dementia. She is also deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration.
Prof James Rowe
Prof of Cognitive Neurology at the University of Cambridge, practicing consultant neurologist & Director @Cambridge Centre for Frontotemporal Dementia and Related Disorder
Prof Rowe is an Associate Director of Dementias Platform UK and leads the Experimental Medicine Incubator (EMI) and the Synaptic Health theme within the EMI. His research aims to protect brain function in those at risk of dementia, and restore brain function in those with symptoms.
Prof Bart De Strooper
UK DRI Director, Group Leader at UK DRI at UCL and VIB, KULeuven
Prof De Strooper is a world-leading dementia discovery scientist, pioneering investigation on the secretases and proteases which cleave the amyloid precursor protein (APP), and are implicated in Alzheimer’s. His current studies focus on the complex cellular phase of the disease using single cell, genome wide transcription profiling with spatial and temporal resolution.
Dr Giovanna Lalli
UK DRI Director of Scientific Affairs
Dr Lalli joined the UK DRI as Director of Scientific Affairs in September 2018, following three years at Wellcome as Senior Portfolio Developer and Acting Head of Neuroscience and Mental Health. She has over 20 years of research experience, including a 7-year period as principal investigator and lecturer in molecular neurobiology at King’s College London.
Prof Clare Mackay
Professor of Imaging Neuroscience at the University of Oxford, Associate Director @Oxford Centre for Human Brain Activity (OHBA), Theme Lead, NIHR Oxford Health BRC (Older Adults & Dementia)
Prof. Mackay’s background is in imaging and she has a broad interest in biomarkers. She has recently pioneered the Oxford Brain Health Clinic as a translational interface to improve diagnostics and develop pathways for personalised risk reduction.